# Retatrutide + Cagrilintide

> 15 mg co-formulated vial combining a triple incretin agonist and an amylin analogue

All products are sold strictly for laboratory research use only. Not for human or veterinary use.

- Web page: https://peptidemedixeu.com/en/products/retatrutide-cagrilintide/
- Brand: Peptide Medix EU
- Category: [Weight Management Blends](https://peptidemedixeu.com/en/collections/weight-management-blends/)
- Purity: ≥99% by HPLC per component; lot-matched COA
- from €204 (EUR)

## Sizes and prices (EUR)

| Size | Price | SKU |
| --- | --- | --- |
| 15 mg · (12.5/2.5) | €204 | RETATRUTIDE-CAGRILINTIDE-15-MG-12-5-2-5 |

_Catalog prices at build time; the web page and checkout are authoritative._

## Specifications

- **Form:** Lyophilized powder, sealed glass vial
- **Purity:** ≥99% by HPLC per component; lot-matched COA
- **Solubility:** Bacteriostatic water; add slowly and avoid agitation
- **Storage (lyophilized):** −20 °C, protected from light and moisture
- **Storage (reconstituted):** 2–8 °C, protected from light
- **Product type:** Two-peptide metabolic research blend, single vial
- **Components:** Retatrutide (LY3437943) and cagrilintide (AM833)
- **Total peptide content:** 15 mg per vial — retatrutide 12.5 mg, cagrilintide 2.5 mg
- **Retatrutide:** CAS 2381089-83-2 · C221H342N46O68 · 4731.30 g/mol
- **Cagrilintide:** CAS 1415456-99-3 · C194H309N55O59S2 · 4409.07 g/mol
- **Retatrutide class:** GIP / GLP-1 / glucagon triple receptor agonist, 39 residues
- **Cagrilintide class:** Long-acting amylin and calcitonin receptor agonist, 32 residues
- **Research areas:** Incretin and amylin receptor signalling, energy balance, metabolic models

## Description

This vial combines two of the metabolic peptides that have attracted the most research in the past ten years. Retatrutide is a synthetic analogue of 39 residues engineered to activate three receptors together — those for GIP, GLP-1 and glucagon — and a fatty side chain keeps it in circulation for longer. Cagrilintide is a long-lasting analogue of amylin, a hormone the pancreas releases alongside insulin, and acts through populations of amylin and calcitonin receptors.

Peptide Medix EU delivers the blend freeze-dried in a sealed glass vial. Each of the two components is HPLC-assayed to ≥99% purity, and the lot is released with its own certificate of analysis; as both peptides are big and structurally complex, the certificate reports each of them separately. The product is a research chemical intended solely for laboratory studies. It is not a medicine, has no authorisation for any use in people, and comes without any dosing information.

## Frequently asked questions

### In what ratio are the peptides present?

12.5 mg of retatrutide and 2.5 mg of cagrilintide — 15 mg in total, split 5:1 by weight. Their molecular weights are close (about 4,731 g/mol for retatrutide and 4,409 g/mol for cagrilintide), so in moles the ratio ends up almost the same as by weight.

### What is the reason for pairing an incretin agonist with an amylin analogue?

The two act on different receptor families: retatrutide on GIP, GLP-1 and glucagon receptors, cagrilintide on amylin and calcitonin receptors. Studies that want both signalling arms in one preparation use a co-formulation instead of two vials.

### Does the COA cover each component separately?

Yes. Because the vial contains two peptides, the lot certificate states HPLC identity and purity for retatrutide and for cagrilintide individually, not as one combined figure. We can send you the latest version before you order.

### Can I change the ratio between the two?

Not from this vial — combining them fixes the split at 12.5 mg to 2.5 mg. If your study needs to change the amount of one peptide independently, use retatrutide and cagrilintide from separate vials; Peptide Medix EU stocks both on their own, in several sizes.

---

All products offered on this website are intended solely for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics or dietary supplements, and are not intended to diagnose, treat, cure or prevent any disease. Products must not be introduced into humans or animals in any manner. By purchasing, you confirm that you are a qualified researcher and accept full responsibility for handling and storage in accordance with applicable laws.

Peptide Medix EU · https://peptidemedixeu.com/en/products/retatrutide-cagrilintide/